Alternatives to FamGenix: a 2026 field guide for clinical pedigree software

Looking for an alternative to FamGenix? Here's an honest field guide. FamGenix is a genuinely strong clinical product, particularly for hereditary cancer risk assessment — it runs BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, and QRISK3 simultaneously from a single pedigree, offers a free Individual tier, and publishes tiered pricing. That combination is hard to beat in the cancer-risk niche. Most teams who reach this page are not looking to replace FamGenix because it is failing; they are looking to evaluate it against peers for workflows that extend beyond cancer risk, or to add capabilities (AI interpretation, programmatic access, broader disease coverage) that FamGenix does not currently offer.

This page covers four serious alternatives — TrakGene, Phenotips, Progeny, and Evagene. We are honest about where FamGenix is better: no alternative listed here matches it on cancer-risk breadth. We are equally honest about where each alternative is better: broader clinical scope, AI interpretation, programmatic platform access, or HPO phenotyping depth, depending on the alternative. Evagene publishes this site; we mark its gaps (BOADICEA, Tyrer-Cuzick, published pricing) as plainly as its strengths.

Short version. For cancer-risk-only practice, stay with FamGenix — its model breadth leads the category. For broader clinical genetics with AI and API surfaces, Evagene. For HPO-driven rare disease, Phenotips. For established FHIR-integrated enterprise use, TrakGene. For continuity with legacy enterprise clinical genetics, Progeny.

Why teams look for alternatives to FamGenix

The main reason is scope. FamGenix concentrates on hereditary cancer risk, which is exactly why its model breadth is so strong. Services whose work extends into cardiac genetics, reproductive genetics, rare disease diagnostics, or general Mendelian inheritance often need a broader clinical platform. They may continue to use FamGenix for cancer risk and add another tool for the rest — but one consolidated platform is usually preferred.

The second reason is modern workflow surface. AI-assisted draft summaries, REST APIs, webhooks, Model Context Protocol agents, and embeddable pedigree viewers are not among FamGenix's advertised features in 2026. Services building EHR integration layers, AI agents, or internal tools often find another platform's programmatic surface more fit-for-purpose. A third reason, less common, is a preference for cloud-first architecture and a modern interaction model — FamGenix is a clinical product rather than a platform, and some teams want a platform.

Four alternatives worth evaluating

TrakGene

TrakGene is a clinician-built clinical genetics platform with HL7 FHIR-first integration and a public customer list including NIH, NHS services, and Geisinger. It is a broader clinical genetics platform than FamGenix and is particularly strong where EHR integration matters.

Where TrakGene fits as a FamGenix alternative: services that need FHIR-native EHR integration alongside pedigree work. Where it falls short: TrakGene does not publicly advertise BOADICEA v6 or Tyrer-Cuzick v8; if cancer-risk model breadth is the reason you chose FamGenix, TrakGene will not match it. Public pricing is not available, so procurement is heavier than FamGenix's published tiers.

Phenotips

Phenotips is an enterprise Genomic Health Record platform with the Human Phenotype Ontology (HPO) at its core. With 100,000+ records across 60+ countries per its homepage, it is well-established in rare disease diagnostics and phenotype-driven gene suggestion.

Where Phenotips fits as a FamGenix alternative: services whose work centres on undiagnosed rare disease and HPO phenotyping. Where it falls short: Phenotips is not positioned as a hereditary cancer risk platform and does not publicly enumerate the cancer risk models it runs. Enterprise sales-led procurement removes the lightweight evaluation path FamGenix offers via its free Individual tier. If your FamGenix use is cancer-focused, Phenotips is not the natural alternative.

Progeny

Progeny is one of the longest-running clinical pedigree vendors (product history reaching back to 1996), with a broad clinical genetics suite, research cohort tooling, and EHR integration. Its strengths are longevity, proven deployments, and a mature feature set.

Where Progeny fits: institutions that want a vendor with decades of clinical footprint and that need cohort-management features. Where it falls short relative to FamGenix: third-party reports cite rising pricing and an architectural heritage that predates modern cloud patterns. FamGenix's published pricing and free tier are a more accessible evaluation path than Progeny's enterprise sales cycle.

Evagene

Evagene is a modern, browser-first pedigree-modelling platform. It covers gesture-driven pedigree drawing with NSGC/ISCN notation, a 230+ disease catalogue cross-referenced to five ontology systems — ICD-10, OMIM, MONDO, Orphanet, and Disease Ontology (DOID), searchable by CURIE — cancer family-history models including Gail/BCRAT and an IBIS-style Tyrer-Cuzick approximation (a research/teaching approximation of the published Tyrer/Duffy/Cuzick 2004 algorithm, not the official IBIS binary) plus Claus, Couch, Frank, Manchester, NICE, Amsterdam II and revised Bethesda, the BayesMendel BRCAPRO/MMRpro/PancPRO models, and an educational prostate-cancer model, Mendelian inheritance calculators for AD, AR, and XR conditions, batch risk screening across the disease catalogue, a karyogram viewer, and consanguinity detection via Wright's coefficient. A 2026 release added educational HPO phenotyping (browse/search a curated Human Phenotype Ontology catalogue and attach observed or excluded features with onset and severity) with phenotype-to-gene educational associations that surface candidate associated genes as reference data — candidate associations only, never a ranked likelihood, nothing asserted about a person, no diagnosis.

Where Evagene differs from FamGenix: a broader educational scope (rare disease, Mendelian, consanguinity, cardiogenetic conditions through its catalogue), 21 built-in published risk-model algorithms presented as illustrative and for teaching — the latest being an educational prostate-cancer family-history model that widens the illustrative set and references external guidelines only with an explicit "Evagene does not make this recommendation" caveat — and a modern platform surface. AI-assisted draft summaries for educational / research review use bring-your-own-key (BYOK) LLMs for Anthropic Claude and OpenAI GPT, so text goes directly to your own LLM contract. Analysis Templates codify a house style for AI-drafted summaries. A gated relatedness / IBD analysis module computes pairwise kinship coefficients, per-individual inbreeding, Jacquard condensed-identity / expected genome-wide IBD sharing (k0/k1/k2), and a gene-dropping relatedness simulation for educational and research use. The MCP server exposes 27 tools to AI agents such as Claude Desktop and Claude Code, and the "Evagene Pedigree Builder" ChatGPT Custom GPT turns natural-language family history into a pedigree. A guided Family History Questionnaire runs intake through to a pedigree, and the Related Concepts educational correlation graph surfaces 1,100+ curated associations (reference data, not risk analysis). A scoped REST API, HMAC-SHA256 webhooks, and the embeddable pedigree viewer (iframe/SVG/JS) open the product to integration in ways FamGenix does not advertise. Data interoperability includes GEDCOM 5.5.1, GA4GH Phenopackets v2 (import and export), JSON, 23andMe, XEG, and pedigree image OCR.

Where Evagene falls short against FamGenix: it does not bundle BOADICEA v6 — that model is licensed by the University of Cambridge, so Evagene exports a ##CanRisk 2.0 pedigree file for the canonical run at canrisk.org rather than computing BOADICEA in-app — its Tyrer-Cuzick is an IBIS-style approximation rather than the official IBIS v8 binary, and it does not run QRISK3. FamGenix runs official BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, and QRISK3 simultaneously from one pedigree, which for a breast/ovarian-dominated clinical practice is a genuine advantage. Pricing is not yet published (Evagene is in Alpha with free access via waiting list), so direct price comparison with FamGenix's tiers is not possible today. For services whose work is broader and that want AI and programmatic access alongside cancer risk, Evagene is the intended fit.

Feature comparison matrix

Compiled from publicly available product pages as of June 2026. "—" means not publicly advertised.

How to choose

Cancer-risk-only practice. Stay with FamGenix. No listed alternative matches BOADICEA v6 + Tyrer-Cuzick v8 + Gail + Claus + QRISK3 simultaneously today.

Balanced clinical genetics with cancer plus Mendelian and rare disease. Evagene — a 21-model illustrative risk suite (Gail/BCRAT, an IBIS-style Tyrer-Cuzick approximation, Claus/Couch/Frank/Manchester/NICE/Amsterdam II/revised Bethesda, BayesMendel BRCAPRO/MMRpro/PancPRO and an educational prostate model) with a CanRisk/BOADICEA export bridge, Mendelian calculators, batch screening across a 230+ disease catalogue cross-referenced to ICD-10/OMIM/MONDO/Orphanet/DOID, a guided Family History Intake, educational HPO phenotyping, relatedness/IBD analysis, AI-assisted draft summaries, and programmatic access (REST API, 27-tool MCP server, Phenopackets v2). Accept that BOADICEA is exported rather than bundled, the Tyrer-Cuzick is an IBIS-style approximation, and QRISK3 is absent.

HPO-first rare disease. Phenotips. HPO depth is its defining feature.

Modern FHIR-native platform. TrakGene if FHIR is non-negotiable; Evagene for generic REST-API-style integration.

Established enterprise continuity. Progeny retains institutional trust for long-horizon deployments.

Frequently asked questions

Further reading

• Hereditary cancer risk assessment
• Phenotips vs Evagene
• Progeny vs Evagene
• Clinical genetics pedigree tools: a field guide
• Mendelian inheritance calculator
• Pedigree drawing software
• The Evagene platform layer (API, MCP, webhooks)